Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JV-213 in Relapsed or Refractory B-cell Lymphomas
NCT05773040Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD79b CAR-T cells in B cell lymphoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events and Maximum Tolerated Dose. Started Apr 2023; status: recruiting.
02
Drugs
CD79b CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05773040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773040.